Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars

Boehringer Ingelheim files Citizen Petition for interpretation

Dec 2, 2020

Boehringer Ingelheim filed a Citizen Petition asking the Commissioner of Food and Drugs to interpret the term ‘strength’ in s 351(k) of the PHS Act for parenteral solutions to mean ‘total drug content’. The current interpretation does not allow a biological product to be licensed as a biosimilar and/or interchangeable product if there is any variation in inactive drug volume. BI has argued that the proposed interpretation may increase access to more affordable biosimilar and interchangeable biological products.

Print Page Mail Article